| Mr Jay Allen Shepherd, MD | |
|
2201 Lexington Ave, Ashland, KY 41101-2843 | |
| (606) 408-4000 | |
| Not Available |
| Full Name | Mr Jay Allen Shepherd |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 17 Years |
| Location | 2201 Lexington Ave, Ashland, Kentucky |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1477731842 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 44291 (Kentucky) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Cabell Huntington Hospital Inc | Huntington, WV | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| River Cities Anesthesia Pllc | 6002707015 | 60 |
| Northstar Anesthesia Of West Virginia Pllc | 2668750241 | 112 |
| River Cities Anesthesia Pllc | 6002707015 | 60 |
News Archive
Chicago-based Accretive Health agrees to pay $2.5 million and end operations in the state for at least two years to settle charges that it violated federal law requiring hospitals to provide emergency care even if people cannot afford to pay.
The business fills a niche in the world market by manufacturing custom-made tools (antibodies) used in the study of proteins. Antibodies for use in typical laboratory subjects such as mammals are easily obtained, but it is very difficult to find these tools for use with other organisms, such as fish, plants, and algae. Recognizing the need for these products through his own research at Mount A over the last six years, Campbell appreciated the innovative applications of his findings.
Meda announced today positive results of three studies of MP29-02 (tentatively called Dymista), a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate.
Oncolytics Biotech Inc. announced today that the Children's Oncology Group (COG) intends to conduct a Phase I trial of REOLYSIN in combination with cyclophosphamide in pediatric patients with relapsed or refractory solid tumors.
Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) today announced positive results from formal studies of its BDM-E eye disease drug, presented over 21 – 22 July at the International Society for Eye Research (ISER) meeting in Berlin, Germany. The ISER convenes leading researchers and clinicians in the area of eye disease.
› Verified 8 days ago
| Entity Name | River Cities Anesthesia Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699845164 PECOS PAC ID: 6002707015 Enrollment ID: O20040322000460 |
News Archive
Chicago-based Accretive Health agrees to pay $2.5 million and end operations in the state for at least two years to settle charges that it violated federal law requiring hospitals to provide emergency care even if people cannot afford to pay.
The business fills a niche in the world market by manufacturing custom-made tools (antibodies) used in the study of proteins. Antibodies for use in typical laboratory subjects such as mammals are easily obtained, but it is very difficult to find these tools for use with other organisms, such as fish, plants, and algae. Recognizing the need for these products through his own research at Mount A over the last six years, Campbell appreciated the innovative applications of his findings.
Meda announced today positive results of three studies of MP29-02 (tentatively called Dymista), a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate.
Oncolytics Biotech Inc. announced today that the Children's Oncology Group (COG) intends to conduct a Phase I trial of REOLYSIN in combination with cyclophosphamide in pediatric patients with relapsed or refractory solid tumors.
Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) today announced positive results from formal studies of its BDM-E eye disease drug, presented over 21 – 22 July at the International Society for Eye Research (ISER) meeting in Berlin, Germany. The ISER convenes leading researchers and clinicians in the area of eye disease.
› Verified 8 days ago
| Entity Name | Kings Daughters Medical Specialties Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497083539 PECOS PAC ID: 6103968029 Enrollment ID: O20100114000813 |
News Archive
Chicago-based Accretive Health agrees to pay $2.5 million and end operations in the state for at least two years to settle charges that it violated federal law requiring hospitals to provide emergency care even if people cannot afford to pay.
The business fills a niche in the world market by manufacturing custom-made tools (antibodies) used in the study of proteins. Antibodies for use in typical laboratory subjects such as mammals are easily obtained, but it is very difficult to find these tools for use with other organisms, such as fish, plants, and algae. Recognizing the need for these products through his own research at Mount A over the last six years, Campbell appreciated the innovative applications of his findings.
Meda announced today positive results of three studies of MP29-02 (tentatively called Dymista), a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate.
Oncolytics Biotech Inc. announced today that the Children's Oncology Group (COG) intends to conduct a Phase I trial of REOLYSIN in combination with cyclophosphamide in pediatric patients with relapsed or refractory solid tumors.
Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) today announced positive results from formal studies of its BDM-E eye disease drug, presented over 21 – 22 July at the International Society for Eye Research (ISER) meeting in Berlin, Germany. The ISER convenes leading researchers and clinicians in the area of eye disease.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Jay Allen Shepherd, MD Po Box 2379, Ashland, KY 41105-2379 Ph: (606) 408-6200 | Mr Jay Allen Shepherd, MD 2201 Lexington Ave, Ashland, KY 41101-2843 Ph: (606) 408-4000 |
News Archive
Chicago-based Accretive Health agrees to pay $2.5 million and end operations in the state for at least two years to settle charges that it violated federal law requiring hospitals to provide emergency care even if people cannot afford to pay.
The business fills a niche in the world market by manufacturing custom-made tools (antibodies) used in the study of proteins. Antibodies for use in typical laboratory subjects such as mammals are easily obtained, but it is very difficult to find these tools for use with other organisms, such as fish, plants, and algae. Recognizing the need for these products through his own research at Mount A over the last six years, Campbell appreciated the innovative applications of his findings.
Meda announced today positive results of three studies of MP29-02 (tentatively called Dymista), a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate.
Oncolytics Biotech Inc. announced today that the Children's Oncology Group (COG) intends to conduct a Phase I trial of REOLYSIN in combination with cyclophosphamide in pediatric patients with relapsed or refractory solid tumors.
Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) today announced positive results from formal studies of its BDM-E eye disease drug, presented over 21 – 22 July at the International Society for Eye Research (ISER) meeting in Berlin, Germany. The ISER convenes leading researchers and clinicians in the area of eye disease.
› Verified 8 days ago
Dr. Brian Fisher, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 2201 Lexington Ave, Ashland, KY 41101 Phone: 606-408-4000 Fax: 606-408-5176 | |
Edwin Thomas Brott, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 2204 Lexington Avenue, Ashland, KY 41101 Phone: 513-300-0149 | |
Dr. Michael D Nestor, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 1000 St. Christopher Drive, Ashland, KY 41101 Phone: 606-833-3791 | |
Oscar Ernesto Penate, M.D Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 2201 Lexington Ave, Ashland, KY 41101 Phone: 606-408-4000 | |
Leon B Briggs, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 617 23rd St Ste 8b, Ashland, KY 41101 Phone: 606-408-1290 Fax: 606-408-6640 | |
Ronald Louis Newman, DO Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 2201 Lexington Ave, Ashland, KY 41101 Phone: 859-408-4000 Fax: 859-269-4120 | |
Jenawik C Marcum, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 2201 Lexington Avenue, Ashland, KY 41101 Phone: 606-408-6806 Fax: 606-408-6807 |